Rani Therapeutics Holdings, Inc.
RANI
$1.05
-$0.05-4.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 26.04% | -19.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.74% | -30.92% | |||
| Operating Income | -17.61% | 30.92% | |||
| Income Before Tax | -14.66% | 29.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.66% | 29.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -149.20% | -44.79% | |||
| Net Income | -90.41% | 19.13% | |||
| EBIT | -17.61% | 30.92% | |||
| EBITDA | -18.69% | 31.48% | |||
| EPS Basic | 39.83% | 36.37% | |||
| Normalized Basic EPS | 15.40% | 22.53% | |||
| EPS Diluted | -20.77% | 36.37% | |||
| Normalized Diluted EPS | 15.40% | 22.53% | |||
| Average Basic Shares Outstanding | 216.71% | 27.10% | |||
| Average Diluted Shares Outstanding | 216.71% | 27.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||